SEC Form 4 · accession 0000891293-16-000113
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Chief Business Officer
Period of report
Mar 4, 2016
Accepted (ET)
Mar 4, 2016 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 4, 2016 | S | 1,300 | $0.585 | D | 598,784 | D | |
| Common Stock | Mar 4, 2016 | S | 400 | $0.586 | D | 598,384 | D | |
| Common Stock | Mar 4, 2016 | S | 636 | $0.587 | D | 597,748 | D | |
| Common Stock | Mar 4, 2016 | S | 1,500 | $0.588 | D | 596,248 | D | |
| Common Stock | Mar 4, 2016 | S | 844 | $0.589 | D | 595,404 | D | |
| Common Stock | Mar 4, 2016 | S | 700 | $0.59 | D | 594,704 | D | |
| Common Stock | Mar 4, 2016 | S | 700 | $0.591 | D | 594,004 | D | |
| Common Stock | Mar 4, 2016 | S | 200 | $0.592 | D | 593,804 | D | |
| Common Stock | Mar 4, 2016 | S | 1,100 | $0.593 | D | 592,704 | D | |
| Common Stock | Mar 4, 2016 | S | 500 | $0.594 | D | 592,204 | D | |
| Common Stock | Mar 4, 2016 | S | 1,220 | $0.595 | D | 590,984 | D | |
| Common Stock | Mar 4, 2016 | S | 900 | $0.596 | D | 590,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.